

VITAL THERAPIES INC  
Form 8-K  
May 01, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

**May1, 2014**

**VITAL THERAPIES, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36201**  
**(Commission**  
  
**File Number)**

**56-2358443**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: VITAL THERAPIES INC - Form 8-K

**15010 Avenue of Science, Suite 200**

**San Diego, CA 92128**

**(Address of principal executive offices, including zip code)**

**(858) 673-6840**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Information.**

On May 1, 2014, Vital Therapies, Inc. issued a press release announcing that the 100<sup>th</sup> subject in its VTI-208 Phase 3 randomized, controlled clinical trial of 200 subjects with alcohol-induced liver decompensation, or AILD. A copy of this press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of Vital Therapies, Inc., dated May 1, 2014.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**VITAL THERAPIES, INC.**

By: /s/ Michael V. Swanson  
**Michael V. Swanson**

**Chief Financial Officer**

Date: **May 1, 2014**

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of Vital Therapies, Inc., dated May 1, 2014.